REALCAN PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.68 CNY | -.--% |
|
+11.67% | -18.04% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 10,488 | 11,508 | 7,826 | 5,881 | 6,165 | 4,920 |
| Enterprise Value (EV) 1 | 15,960 | 12,989 | 12,117 | 5,846 | 4,829 | 6,684 |
| P/E ratio | 13.5 x | -12.4 x | 24.9 x | 43.7 x | -3.32 x | 242 x |
| Yield | 0.75% | - | 0.34% | 0.23% | - | - |
| Capitalization / Revenue | 0.31 x | 0.33 x | 0.29 x | 0.28 x | 0.5 x | 0.61 x |
| EV / Revenue | 0.47 x | 0.37 x | 0.45 x | 0.28 x | 0.39 x | 0.83 x |
| EV / EBITDA | 5.38 x | 4.66 x | 7.21 x | 5.33 x | 36.8 x | 44.4 x |
| EV / FCF | -5.98 x | 3.2 x | -4.62 x | 1.03 x | 0.98 x | -1.95 x |
| FCF Yield | -16.7% | 31.3% | -21.7% | 97.1% | 102% | -51.3% |
| Price to Book | 1.24 x | 1.58 x | 1.05 x | 0.78 x | 1.14 x | 0.91 x |
| Nbr of stocks (in thousands) | 1,504,710 | 1,496,437 | 1,496,437 | 1,496,437 | 1,496,437 | 1,504,710 |
| Reference price 2 | 6.970 | 7.690 | 5.230 | 3.930 | 4.120 | 3.270 |
| Announcement Date | 4/29/19 | 4/28/20 | 3/30/21 | 4/29/22 | 4/28/23 | 4/29/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 33,919 | 35,259 | 27,204 | 21,060 | 12,311 | 8,034 |
| EBITDA 1 | 2,965 | 2,789 | 1,680 | 1,097 | 131.2 | 150.4 |
| EBIT 1 | 2,737 | 2,521 | 1,402 | 813.4 | -108.7 | -64.78 |
| Operating Margin | 8.07% | 7.15% | 5.16% | 3.86% | -0.88% | -0.81% |
| Earnings before Tax (EBT) 1 | 1,963 | 102.4 | 915.5 | 465 | -1,744 | -135.4 |
| Net income 1 | 778.7 | -927.8 | 261.3 | 131.2 | -1,832 | 20.32 |
| Net margin | 2.3% | -2.63% | 0.96% | 0.62% | -14.88% | 0.25% |
| EPS 2 | 0.5170 | -0.6200 | 0.2100 | 0.0900 | -1.242 | 0.0135 |
| Free Cash Flow 1 | -2,667 | 4,062 | -2,624 | 5,678 | 4,920 | -3,428 |
| FCF margin | -7.86% | 11.52% | -9.65% | 26.96% | 39.96% | -42.66% |
| FCF Conversion (EBITDA) | - | 145.67% | - | 517.63% | 3,751.01% | - |
| FCF Conversion (Net income) | - | - | - | 4,328.4% | - | - |
| Dividend per Share 2 | 0.0520 | - | 0.0180 | 0.009000 | - | - |
| Announcement Date | 4/29/19 | 4/28/20 | 3/30/21 | 4/29/22 | 4/28/23 | 4/29/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 5,472 | 1,481 | 4,290 | - | - | 1,764 |
| Net Cash position 1 | - | - | - | 34.8 | 1,336 | - |
| Leverage (Debt/EBITDA) | 1.845 x | 0.5312 x | 2.553 x | - | - | 11.73 x |
| Free Cash Flow 1 | -2,667 | 4,062 | -2,624 | 5,678 | 4,920 | -3,428 |
| ROE (net income / shareholders' equity) | 12.2% | -4.03% | 6.02% | 3.78% | -22.5% | 0.56% |
| ROA (Net income/ Total Assets) | 5.53% | 4.68% | 2.75% | 1.74% | -0.3% | -0.23% |
| Assets 1 | 14,072 | -19,823 | 9,503 | 7,552 | 602,914 | -8,796 |
| Book Value Per Share 2 | 5.620 | 4.870 | 4.990 | 5.060 | 3.610 | 3.600 |
| Cash Flow per Share 2 | 2.040 | 3.270 | 3.830 | 3.060 | 3.570 | 3.340 |
| Capex 1 | 604 | 935 | 505 | 461 | 171 | 298 |
| Capex / Sales | 1.78% | 2.65% | 1.86% | 2.19% | 1.39% | 3.71% |
| Announcement Date | 4/29/19 | 4/28/20 | 3/30/21 | 4/29/22 | 4/28/23 | 4/29/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -18.04% | 557M | |
| +16.03% | 70.59B | |
| +2.22% | 25.06B | |
| +7.11% | 8.2B | |
| -2.98% | 7.92B | |
| -20.55% | 7.96B | |
| +3.11% | 4.71B | |
| +17.12% | 4.32B | |
| -1.24% | 4.01B | |
| -3.44% | 3.82B |
- Stock Market
- Equities
- 002589 Stock
- Financials Realcan Pharmaceutical Group Co., Ltd.
